Evaluation of the morphological effects of TDT 067 (terbinafine in transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2530-2534

  Ghannoum, M ^a   Isham, N ^a   Henry, W ^b   Kroon, H A ^c   Yurdakul, S ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Celtic Pharma Development Services Europe Ltd   (United Kingdom)

^c Celtic Pharmaceutical Development Services America Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TDT 067; TERBINAFINE; UNCLASSIFIED DRUG;

ARTICLE; DERMATOPHYTE; DRUG EFFECT; FUNGUS HYPHAE; HUMAN; IN VITRO STUDY; INTRACELLULAR SPACE; NONHUMAN; ONYCHOMYCOSIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; TRICHOPHYTON RUBRUM;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DRUG CARRIERS; HUMANS; HYPHAE; MICROSCOPY, ELECTRON, SCANNING; NAILS; NAPHTHALENES; PERMEABILITY; PHOSPHOLIPIDS; POLYSORBATES; SKIN; TINEA; TRICHOPHYTON; UNITED STATES;

EID: 84860163827     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05998-11     Document Type: Article

References (29)

1. Ajit C, Suvannasankha A, Zaeri N, Moniz SJ. 2003. Terbinafine-induced hepatotoxicity. Am. J. Med. Sci. 325:292-295.
2. Benson HA. 2006. Transfersomes for transdermal drug delivery. Expert Opin. Drug Deliv. 3:727-737. (Pubitemid 44781845)
3. Cevc G. 1997. Drug delivery across the skin. Expert Opin. Invest. Drugs 6:1887-1937. (Pubitemid 27517593)
4. Chandra J, et al. 2001. Antifungal resistance of Candida biofilms formed on denture acrylic in vitro. J. Dent. Res. 80:903-908. (Pubitemid 32477425)
5. Crawford F, Hollis S. 2007. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst. Rev. 3:CD001434.
6. Dominicus R, Weidner C, Tate H, Kroon H-A. 2 December 2011. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome) in patients with onychomycosis. Br. J. Dermatol. doi:10.1111/j.1365-2133.2011.10766.x. [Epub ahead of print.]
7. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. 2005. Epidemiology and clinical classification of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 19(Suppl 1):8-12. (Pubitemid 41726923)
8. Favre B, Ryder NS. 1996. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob. Agents Chemother. 40: 443-447. (Pubitemid 26049358)
9. Ghannoum MA, et al. 2000. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. 43:641-648.
10. Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S. 2011. Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J. Clin. Microbiol. 49:1716-1720.
11. Gupta AK, et al. 2000. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. 43(2 Pt 1):244-248. (Pubitemid 30626001)
12. Hanaichi T, Funahashi A, Fujitsuka N, Yoshimura A, Ito F. 1986. Ultra structural aspects of the capsular cells in frog muscle spindle. Okajimas Folia Anat. Jpn. 62:281-293.
13. Haneke E. 1999. Achilles foot-screening project: background, objectives and design. J. Eur. Acad. Dermatol. Venereol. 12(Suppl 1):S2-S5; discussion S17.
14. Isenberg HD. 1992. Clinical microbiology procedures handbook, section 6.3. American Society for Microbiology, Washington, DC.
15. Katz HI. 1999. Drug interactions of the newer oral antifungal agents. Br. J. Dermatol. 141(Suppl 56):26-32.
16. Kneer W, Rother I, Rother M, Seidel E. 2009. A multiple-dose, openlabel, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr. Drug Saf. 4:5-10.
17. Meingassner JG, Sleytr U, Petranyi G. 1981. Morphological changes induced by naftifine, a new antifungal agent, in Trichophyton mentagrophytes. J. Investig. Dermatol. 77:444-451. (Pubitemid 12250438)
18. Murdan S. 2008. Enhancing the nail permeability of topically applied drugs. Expert Opin. Drug Deliv. 5:1267-1282.
19. Osborne CS, Leitner I, Favre B, Ryder NS. 2004. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med. Mycol. 42:159-163. (Pubitemid 38489025)
20. Perveze Z, et al. 2007. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 13:162-164. (Pubitemid 46099987)
21. Roberts DT. 1994. Oral therapeutic agents in fungal nail disease. J. Am. Acad. Dermatol. 31(3 Pt 2):S78-S81. (Pubitemid 24280354)
22. Rother M, Lavins BJ, Kneer W, Lehnhardt K. 2007 Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann. Rheum. Dis. 66:1178-1183. (Pubitemid 47309734)
23. Ryder NS. 1992. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br. J. Dermatol. 126(Suppl 39):2-7.
24. Saunte DM, et al. 2006. Prevalence of toenail onychomycosis in diabetic patients. Acta Derm. Venereol. 86:425-428. (Pubitemid 44450099)
25. Sommer S, Sheehan-Dare RA, Goodfield MJ, Evans EG. 2003. Prediction of outcome in the treatment of onychomycosis. Clin. Exp. Dermatol. 28:425-428. (Pubitemid 36801850)
26. Tosti A, Hay R, Arenas-Guzmán R. 2005. Patients at risk of onychomycosis-risk factor identification and active prevention. J. Eur. Acad. Dermatol. Venereol. 19(Suppl 1):13-16. (Pubitemid 41726924)
27. Tschen EH, Jones TM, Kroon H-A. 2011. Safety and pharmacokinetics of TDT 067 under conditions of maximal use in onychomycosis of the toenails, abstr CARL8-0130. Eur. Acad. Dermatol. Venereol. Spring Symp.
28. Vander Straten MR, Hossain MA, Ghannoum MA. 2003. Cutaneous infections dermatophytosis, onychomycosis and tinea versicolor. Infect. Dis. Clin. North Am. 17:87-112. (Pubitemid 36514572)
29. Vender RB, Lynde CW, Poulin Y. 2006. Prevalence and epidemiology of onychomycosis. J. Cutan. Med. Surg. 10(Suppl 2):S28-S33.